Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Nowotwory. Journal of Oncology
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Editorial Office Manuscript Submission Reviewers 2023 Best Original Paper Award

open access

Vol 73, No 1 (2023)
Research paper (original)
Published online: 2022-12-19
View PDF Download PDF file Supp./Additional Files [2]
Get Citation

Morbidity and mortality trends of the most common cancers in 1990–2019. Poland’s position compared to other European countries

Marta J. Miklewska12, Klaudia Barańska13, Urszula Wojciechowska1, Urszula Sulkowska1, Jerzy E. Tyczyński1, Joanna A. Didkowska14
DOI: 10.5603/NJO.a2022.0065
·
Nowotwory. Journal of Oncology 2023;73(1):46-55.
Affiliations
  1. Polish National Cancer Registry, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
  2. Department of Dietetics, Institute of Human Nutrition Sciences, Warsaw University of Life Sciences, Warsaw, Poland
  3. Faculty of Biomedical Engineering, Silesian University of Technology, Zabrze, Poland
  4. Department of Epidemiology and Cancer Prevention, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

open access

Vol 73, No 1 (2023)
Cancer epidemiology
Published online: 2022-12-19

Abstract

Introduction. The purpose of the study was to evaluate the trends in morbidity and mortality of the selected cancer sites in Poland against other European countries.

Material and methods. Countries for analysis were selected based on geographical location. Estimates of age-adjusted incidence and mortality rates were calculated using the new European 2013 standard population. Lung, colorectal, breast, and prostate cancers were chosen. Time trends for age-standardized rates were analyzed using Joinpoint Re­gression software.

Results. Poland differed from other analyzed countries mainly in terms of cancer mortality. Poland is a country with one of the smallest amounts of current expenditures on health care per capita, which translates into one of the highest levels of cancer mortality in both women and men.

Conclusions. Compared to other countries, Poland’s cancer outcomes on population level are unsatisfactory. The si­tuation may improve with the introduction of educational and screening programs.

Abstract

Introduction. The purpose of the study was to evaluate the trends in morbidity and mortality of the selected cancer sites in Poland against other European countries.

Material and methods. Countries for analysis were selected based on geographical location. Estimates of age-adjusted incidence and mortality rates were calculated using the new European 2013 standard population. Lung, colorectal, breast, and prostate cancers were chosen. Time trends for age-standardized rates were analyzed using Joinpoint Re­gression software.

Results. Poland differed from other analyzed countries mainly in terms of cancer mortality. Poland is a country with one of the smallest amounts of current expenditures on health care per capita, which translates into one of the highest levels of cancer mortality in both women and men.

Conclusions. Compared to other countries, Poland’s cancer outcomes on population level are unsatisfactory. The si­tuation may improve with the introduction of educational and screening programs.

Full Text:

View PDF Download PDF file Supp./Additional Files [2]
Get Citation

Keywords

mortality; morbidity; Europe; neoplasms; Poland

Supp./Additional Files (2)
Mortality APC
Download
33KB
Incidence APC
Download
29KB
About this article
Title

Morbidity and mortality trends of the most common cancers in 1990–2019. Poland’s position compared to other European countries

Journal

Nowotwory. Journal of Oncology

Issue

Vol 73, No 1 (2023)

Article type

Research paper (original)

Pages

46-55

Published online

2022-12-19

Page views

2828

Article views/downloads

293

DOI

10.5603/NJO.a2022.0065

Bibliographic record

Nowotwory. Journal of Oncology 2023;73(1):46-55.

Keywords

mortality
morbidity
Europe
neoplasms
Poland

Authors

Marta J. Miklewska
Klaudia Barańska
Urszula Wojciechowska
Urszula Sulkowska
Jerzy E. Tyczyński
Joanna A. Didkowska

References (45)
  1. Sheiman I, Shishkin S, Shevsky V. The evolving Semashko model of primary health care: the case of the Russian Federation. Risk Manag Healthc Policy. 2018; 11: 209–220.
    CrossRefPubMed
  2. Puchta P. Polish Healthcare System in Transition - Perceptions of the OLD and NEW Systems n.d.:67.
  3. Sagan A, Panteli D, Borkowski W, et al. Europe WHORO for, Policies EO on HS. Poland: health system review. 2011.
  4. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–249.
    CrossRefPubMed
  5. Cancer statistics - specific cancers. n.d. https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Cancer_statistics_-_specific_cancers (25.10.2022).
  6. Didkowska J, Wojciechowska U, Michalek IM, et al. Cancer incidence and mortality in Poland in 2019. Sci Rep. 2022; 12(1): 10875.
    CrossRefPubMed
  7. Raporty | KRN n.d. http://onkologia.org.pl/raporty/ (25.10.2022).
  8. Główny Urząd Statystyczny. n.d. https://stat.gov.pl/ (25.10.2022).
  9. Startseite - STATISTIK AUSTRIA - Die Informationsmanager. n.d. https://www.statistik.at/ (25.10.2022).
  10. SVOD. n.d. https://svod.cz/ (25.10.2022).
  11. Nordcan 2.0. n.d. https://nordcan.iarc.fr/en (25.10.2022).
  12. PxWeb - Select table. n.d. https://statistika.tai.ee/pxweb/en/Andmebaas/Andmebaas__04THressursid (25.10.2022).
  13. WHO cancer mortality database (IARC). n.d. https://www-dep.iarc.fr/WHOdb/WHOdb.htm (25.10.2022).
  14. European Cancer Information System. n.d. https://ecis.jrc.ec.europa.eu/index.php (25.10.2022).
  15. National Health Information Center. n.d. https://www.nczisk.sk/en/Pages/default.aspx (25.10.2022).
  16. Cancer Registries. n.d. https://www.onko-i.si/eng/crs (25.10.2022).
  17. European Commission, Eurostat. Revision of the European Standard Population: report of Eurostat’s task force: 2013 edition. LU: Publications Office 2013.
  18. Kim HJ, Fay M, Feuer E, et al. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2001; 19(3): 335–351, doi: 10.1002/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z.
  19. Hitiris T, Posnett J. The determinants and effects of health expenditure in developed countries. J Health Econ. 1992; 11(2): 173–181.
    CrossRefPubMed
  20. File:Current healthcare expenditure, 2019.png. n.d. https://ec.europa.eu/eurostat/statistics-explained/index.php?title=File:Current_healthcare_expenditure,_2019.png (18.11.2022).
  21. Cancer Prevention Overview (PDQ®)–Patient Version - NCI. 2009. https://www.cancer.gov/about-cancer/causes-prevention/patient-prevention-overview-pdq (18.11.2022).
  22. Parkin DM, Boyd L, Walker LC. 16. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. Br J Cancer. 2011; 105 Suppl 2(Suppl 2): S77–S81.
    CrossRefPubMed
  23. Danaei G, Hoorn SV, Lopez A, et al. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet. 2005; 366(9499): 1784–1793.
    CrossRef
  24. European Code Against Cancer - About the code. n.d. https://cancer-code-europe.iarc.fr/index.php/en/about-code (18.11.2022).
  25. Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ. 2000; 321(7257): 323–329.
    CrossRefPubMed
  26. Didkowska J, Wojciechowska U, Mańczuk M, et al. Lung cancer epidemiology: contemporary and future challenges worldwide. Ann Transl Med. 2016; 4(8): 150.
    CrossRefPubMed
  27. Graham H. Smoking prevalence among women in the European Community 1950–1990. Social Science & Medicine. 1996; 43(2): 243–254.
    CrossRef
  28. Oudkerk M, Devaraj A, Vliegenthart R, et al. European position statement on lung cancer screening. Lancet Oncol. 2017; 18(12): e754–e766.
    CrossRefPubMed
  29. Merriel SWD, Pocock L, Gilbert E, et al. Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC Med. 2022; 20(1): 54.
    CrossRefPubMed
  30. Carr PR, Weigl K, Jansen L, et al. Healthy Lifestyle Factors Associated With Lower Risk of Colorectal Cancer Irrespective of Genetic Risk. Gastroenterology. 2018; 155(6): 1805–1815.e5.
    CrossRefPubMed
  31. Botteri E, Peveri G, Berstad P, et al. Changes in Lifestyle and Risk of Colorectal Cancer in the European Prospective Investigation Into Cancer and Nutrition. Am J Gastroenterol. 2022 [Epub ahead of print].
    CrossRefPubMed
  32. Cancer Screening in the European Union (2017).pdf n.d.
  33. Healthcare activities statistics - preventive services. n.d. https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Healthcare_activities_statistics_-_preventive_services (15.11.2022).
  34. Coleman C. Early Detection and Screening for Breast Cancer. Semin Oncol Nurs. 2017; 33(2): 141–155.
    CrossRefPubMed
  35. Patasius A, Krilaviciute A, Smailyte G. Prostate Cancer Screening with PSA: Ten Years' Experience of Population Based Early Prostate Cancer Detection Programme in Lithuania. J Clin Med. 2020; 9(12).
    CrossRefPubMed
  36. Innos K, Lang K, Pärna K, et al. Age-specific cancer survival in Estonia: recent trends and data quality. Clin Epidemiol. 2015; 7: 355–362.
    CrossRefPubMed
  37. Vutuc C, Schernhammer ES, Haidinger G, et al. Prostate cancer and prostate-specific antigen (PSA) screening in Austria. Wien Klin Wochenschr. 2005; 117(13-14): 457–461.
    CrossRefPubMed
  38. Kjellman A, Akre O, Norming U, et al. 15-year followup of a population based prostate cancer screening study. J Urol. 2009; 181(4): 1615–21; discussion 1621.
    CrossRefPubMed
  39. Ondrusova M, Ondrus D, Karabinos J, et al. Trends in prostate cancer incidence and mortality before and after the introduction of PSA testing in the Slovak and Czech Republics. Tumori. 2011; 97(2): 149–155.
    CrossRefPubMed
  40. Outzen M, Brasso K, Martinussen N, et al. Prostate cancer in Denmark 1978-2009--trends in incidence and mortality. Acta Oncol. 2013; 52(4): 831–836.
    CrossRefPubMed
  41. Tatara T, Miazga W, Świtalski J, et al. Assessment of the effectiveness of clinical PSA concentration measurements in early prostate cancer detection. Nowotwory. Journal of Oncology. 2022; 72(3): 167–173.
    CrossRef
  42. Hugosson J, Carlsson S. Overdetection in screening for prostate cancer. Curr Opin Urol. 2014; 24(3): 256–263.
    CrossRefPubMed
  43. Prajsner A, Chudek J, Szybalska A, et al. PolSenior Study Group. Socioeconomic determinants of prostate-specific antigen testing and estimation of the prevalence of undiagnosed prostate cancer in an elderly Polish population based on the PolSenior study. Arch Med Sci. 2016; 12(5): 1028–1035.
    CrossRefPubMed
  44. COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL Europe’s Beating Cancer Plan 2021.
  45. Lawler M, Davies L, Oberst S, et al. European Groundshot—addressing Europe's cancer research challenges: a Lancet Oncology Commission. Lancet Oncol. 2023; 24(1): e11–e56.
    CrossRef

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl